MA38576B2 - Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières - Google Patents

Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Info

Publication number
MA38576B2
MA38576B2 MA38576A MA38576A MA38576B2 MA 38576 B2 MA38576 B2 MA 38576B2 MA 38576 A MA38576 A MA 38576A MA 38576 A MA38576 A MA 38576A MA 38576 B2 MA38576 B2 MA 38576B2
Authority
MA
Morocco
Prior art keywords
methods
sustained
release
relates
present
Prior art date
Application number
MA38576A
Other languages
English (en)
Other versions
MA38576A1 (fr
Inventor
Susanne Riel
Original Assignee
Murray And Poole Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murray And Poole Enterprises Ltd filed Critical Murray And Poole Enterprises Ltd
Publication of MA38576A1 publication Critical patent/MA38576A1/fr
Publication of MA38576B2 publication Critical patent/MA38576B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des compositions pharmaceutiques de colchicine à administrer une fois par jour par voie orale. Les formulations comprennent un composant à libération prolongée et un composant facultatif à libération immédiate, dont les compositions peuvent être ajustées de façon sélective, respectivement, pour libérer le principe actif selon un profil de libération prédéfini ou souhaité. La présente invention se rapporte également à des méthodes permettant de traiter ou d'empêcher une maladie cardiovasculaire et/ou une maladie inflammatoire chez des sujets mammaliens, lesdites méthodes comprenant l'administration des nouvelles formulations décrites ici.
MA38576A 2013-11-26 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières MA38576B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13194505 2013-11-26
PCT/IB2014/001201 WO2014170755A2 (fr) 2013-04-16 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Publications (2)

Publication Number Publication Date
MA38576A1 MA38576A1 (fr) 2017-05-31
MA38576B2 true MA38576B2 (fr) 2020-02-28

Family

ID=49683519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38576A MA38576B2 (fr) 2013-11-26 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Country Status (19)

Country Link
US (6) US20160081936A1 (fr)
EP (1) EP2986280B1 (fr)
JP (1) JP6480420B2 (fr)
KR (1) KR102271048B1 (fr)
CN (1) CN105307643A (fr)
AU (4) AU2014255434B2 (fr)
BR (1) BR112015026418B1 (fr)
CA (1) CA2909370A1 (fr)
CL (1) CL2015003072A1 (fr)
EA (1) EA037375B1 (fr)
MA (1) MA38576B2 (fr)
MX (2) MX377426B (fr)
MY (2) MY198452A (fr)
PL (1) PL2986280T3 (fr)
PT (1) PT2986280T (fr)
SG (1) SG11201508571WA (fr)
SI (1) SI2986280T1 (fr)
WO (1) WO2014170755A2 (fr)
ZA (1) ZA201507723B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
EP3283063A1 (fr) * 2015-04-17 2018-02-21 Murray And Poole Enterprises Limited Salicylate de colchicine et ses utilisations
US9907751B2 (en) * 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
PL3641726T3 (pl) * 2017-06-23 2026-02-23 Nordiccan A/S Woreczek z kannabinoidami
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
CA3089781A1 (fr) * 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Utilisation de colchicine pour inhiber la croissance tumorale et les metastases
CN110448527B (zh) * 2019-09-23 2021-11-26 杭州百诚医药科技股份有限公司 一种秋水仙碱口服溶液及其处方组成
GB201913827D0 (en) * 2019-09-25 2019-11-06 Cape Peninsula Univ Of Technology Sustained Release Formulation Containing Aspalathus linearis Extract
KR102112456B1 (ko) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
WO2021092703A1 (fr) 2019-11-15 2021-05-20 Institut De Cardiologie De Montreal Procédés d'utilisation de colchicine à faible dose après un infarctus du myocarde
CN111150702B (zh) * 2019-12-04 2021-06-22 复旦大学 一种凝胶药物缓释制剂及其制备方法与应用
KR102584738B1 (ko) 2020-01-17 2023-10-06 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
KR102150821B1 (ko) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
US20240075045A1 (en) * 2020-12-15 2024-03-07 Romeg Therapeutics Llc Methods and compositions for treating pericarditis
CN113476603B (zh) * 2021-07-08 2022-05-20 中南大学 一种红细胞膜包裹的磁性纳米颗粒及其制备方法和应用
CN118717741A (zh) * 2024-01-15 2024-10-01 华中科技大学同济医学院附属协和医院 秋水仙碱在制备用于增加冠状动脉斑块纤维帽厚度药物中的应用
KR102870211B1 (ko) * 2024-06-11 2025-10-16 (주)알피바이오 지속성 제제 조성물
CN121265579A (zh) * 2025-12-11 2026-01-06 华中科技大学同济医学院附属协和医院 秋水仙碱在制备tbk1磷酸化促进剂中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (ja) * 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
WO2002072033A2 (fr) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Formes pharmaceutiques chronotherapeutiques contenant un glucocorticosteroide
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006063091A2 (fr) 2004-12-06 2006-06-15 Ronald Freudenberger Utilisation d'oxypurinol comme inhibiteur de la cardiotoxicite induite par un agent anti-neoplastique
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1748671A (zh) 2005-08-30 2006-03-22 孔庆忠 含抗有丝分裂药物的缓释注射剂
CN1939290A (zh) 2005-09-29 2007-04-04 陆宪光 秋水仙碱及它的衍生物的医学用途
WO2007048004A2 (fr) 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Composes pour ameliorer l'activite des facteurs inductibles par hypoxie et procedes d'utilisation associes
US8697387B2 (en) 2006-06-02 2014-04-15 DiscoverRx Corporation Methods for identifying agents and their use for the prevention of restenosis
AP2416A (en) * 2006-06-09 2012-06-01 Sanol Arznei Schwarz Gmbh Stabilized pharmaceutical compositions comprising fesoterodine.
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
WO2008131192A2 (fr) 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Cholestérol cristallin et prévention de l'athérosclérose
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485638A (zh) * 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 秋水仙碱双层渗透泵控释片及其制备方法
CN101485637B (zh) * 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 秋水仙碱骨架控释片或胶囊
WO2009097450A1 (fr) 2008-01-30 2009-08-06 Dexcom. Inc. Système de capteur à marqueur cardiaque en continu
CN101536990A (zh) * 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 秋水仙碱胃漂浮缓释片及其制备方法
EP2262786A4 (fr) 2008-04-15 2014-07-09 Takeda Pharmaceuticals Usa Inc Formes de colchicine à l état solide, procédés de fabrication et procédés d utilisation associés
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (zh) * 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 秋水仙碱双层缓释片及其制备方法
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
EP2405898A2 (fr) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Composition à libération lente d'un agent thérapeutique
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
CN105193761B (zh) 2009-11-13 2019-12-06 阿斯利康(瑞典)有限公司 双层片剂
EP2481411A1 (fr) * 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
EA028495B1 (ru) 2012-04-13 2017-11-30 Саймабэй Терапьютикс, Инк. Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
BR112015026418B1 (pt) * 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
CN110148563A (zh) 2019-05-23 2019-08-20 武汉新芯集成电路制造有限公司 一种半导体器件及其制造方法

Also Published As

Publication number Publication date
US20200030240A1 (en) 2020-01-30
JP6480420B2 (ja) 2019-03-13
MX377426B (es) 2025-03-10
US20160081936A1 (en) 2016-03-24
US20230414521A1 (en) 2023-12-28
WO2014170755A2 (fr) 2014-10-23
AU2014255434A1 (en) 2015-11-05
MX2020012310A (es) 2021-01-29
US10130585B2 (en) 2018-11-20
US20190054028A1 (en) 2019-02-21
US20150094323A1 (en) 2015-04-02
KR102271048B1 (ko) 2021-06-30
SI2986280T1 (sl) 2021-08-31
SG11201508571WA (en) 2015-11-27
US11648206B2 (en) 2023-05-16
US10105319B2 (en) 2018-10-23
EP2986280B1 (fr) 2021-03-17
MY207496A (en) 2025-02-28
EA201501024A1 (ru) 2016-08-31
AU2019201048B2 (en) 2021-01-28
EP2986280A2 (fr) 2016-02-24
ZA201507723B (en) 2023-05-31
AU2020294268B2 (en) 2024-05-02
CL2015003072A1 (es) 2016-09-23
JP2016521270A (ja) 2016-07-21
MX2015014656A (es) 2016-03-01
AU2014255434B2 (en) 2018-11-08
AU2020294268A1 (en) 2021-01-28
US20150094322A1 (en) 2015-04-02
CN105307643A (zh) 2016-02-03
EA037375B1 (ru) 2021-03-22
MA38576A1 (fr) 2017-05-31
AU2019201048A1 (en) 2019-03-07
BR112015026418B1 (pt) 2022-10-04
US10610488B2 (en) 2020-04-07
PT2986280T (pt) 2021-05-07
AU2024205185A1 (en) 2024-08-15
PL2986280T3 (pl) 2021-10-25
KR20150143725A (ko) 2015-12-23
CA2909370A1 (fr) 2014-10-23
BR112015026418A2 (pt) 2017-07-25
MY198452A (en) 2023-08-29
WO2014170755A3 (fr) 2015-02-19

Similar Documents

Publication Publication Date Title
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
FR2944448B1 (fr) Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
DE602008005643D1 (de) Parathormon-formulierungen und ihre anwendungen
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
EP2586448A4 (fr) Agent d'amélioration des propriétés cutanées, destiné à être administré par voie orale
CY1123372T1 (el) Απο toy στοματος φαρμακευτικη συνθεση
MA32798B1 (fr) Acides naphtylacétiques
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37317A1 (fr) Formulation d'anticorps il-17
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs
EP2164518A4 (fr) Formulations pour l'administration par voie orale d'agents thérapeutiques, et procédés associés
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
FR2940116B1 (fr) Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
MA34106B1 (fr) Combinaison de composés organiques
MA34130B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
EP1940432A4 (fr) Compositions anti-inflammatoires et leurs methodes d'utilisation
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
EP4048244A4 (fr) Système d'administration ingérable par voie orale